IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action.

Lecour, Sandrine; Andreadou, Ioanna; Bøtker, Hans Erik; Davidson, Sean M; Heusch, Gerd; Ruiz-Meana, Marisol; Schulz, Rainer; Zuurbier, Coert J; Ferdinandy, Péter; Hausenloy, Derek J (2021). IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic research in cardiology, 116(1), p. 52. Springer 10.1007/s00395-021-00893-5

[img]
Preview
Text
395_2021_Article_893.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (769kB) | Preview

Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment of Cardioprotective Therapies ('IMPACT'), for investigators to consider adopting before embarking on clinical studies, the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for patient benefit.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Heart Surgery

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1435-1803

Publisher:

Springer

Language:

English

Submitter:

Paul Libera

Date Deposited:

10 Jan 2022 08:16

Last Modified:

27 Feb 2024 14:28

Publisher DOI:

10.1007/s00395-021-00893-5

PubMed ID:

34515837

Additional Information:

Prof. Longnus ist Autorin des European Union-CARDIOPROTECTION COST ACTION CA16225

Uncontrolled Keywords:

Cardioprotection Drug development Infarction Ischemia Reperfusion

BORIS DOI:

10.48350/164324

URI:

https://boris.unibe.ch/id/eprint/164324

Actions (login required)

Edit item Edit item
Provide Feedback